@article{CCO1111,
author = {Valerie Nelson and Alfred Rademaker and Virginia Kaklamani},
title = {Paradigm of polyendocrine therapy in endocrine responsive breast cancer: the role of fulvestrant},
journal = {Chinese Clinical Oncology},
volume = {2},
number = {1},
year = {2012},
keywords = {},
abstract = {Endocrine therapy is the cornerstone of any treatment plan for endocrine-responsive breast cancer in both the adjuvant and metastatic settings (1). In the metastatic setting in post-menopausal patients aromatase inhibitors (AIs; anastrozole, exemestane, letrozole) are standard therapies, shown to demonstrate improved progression-free survival (PFS) and a favorable adverse effect (AE) profile compared to other endocrine agents such as tamoxifen (2,3).},
issn = {2304-3873}, url = {https://cco.amegroups.org/article/view/1111}
}